Annual EBITDA
-$416.14 M
-$73.61 M-21.49%
December 31, 2023
Summary
- As of February 9, 2025, CERE annual EBITDA is -$416.14 million, with the most recent change of -$73.61 million (-21.49%) on December 31, 2023.
- During the last 3 years, CERE annual EBITDA has fallen by -$267.43 million (-179.82%).
Performance
CERE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly EBITDA
-$127.58 M
+$740.00 K+0.58%
March 31, 2024
Summary
- As of February 9, 2025, CERE quarterly EBITDA is -$127.58 million, with the most recent change of +$740.00 thousand (+0.58%) on March 31, 2024.
- Over the past year, CERE quarterly EBITDA has dropped by -$35.44 million (-38.46%).
Performance
CERE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
-$443.48 M
-$27.34 M-6.57%
March 31, 2024
Summary
- As of February 9, 2025, CERE TTM EBITDA is -$443.48 million, with the most recent change of -$27.34 million (-6.57%) on March 31, 2024.
- Over the past year, CERE TTM EBITDA has dropped by -$66.94 million (-17.78%).
Performance
CERE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CERE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.5% | -38.5% | -17.8% |
| 3 y3 years | -179.8% | -89.9% | -87.8% |
| 5 y5 years | -399.7% | -89.9% | -87.8% |
CERE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | +86.9% | at low | +120.1% | +0.6% | +102.1% | at low |
| 5 y | 5-year | +399.7% | at low | +271.8% | +0.6% | +1079.3% | at low |
| alltime | all time | +399.7% | at low | +271.8% | +0.6% | +1079.3% | at low |
Cerevel Therapeutics Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$127.58 M(-0.6%) | -$443.48 M(+6.6%) |
| Dec 2023 | -$416.14 M(+21.5%) | -$128.32 M(+39.3%) | -$416.14 M(+10.5%) |
| Sep 2023 | - | -$92.14 M(-3.4%) | -$376.55 M(-1.4%) |
| Jun 2023 | - | -$95.44 M(-4.8%) | -$381.79 M(+1.6%) |
| Mar 2023 | - | -$100.24 M(+13.0%) | -$375.60 M(+9.7%) |
| Dec 2022 | -$342.53 M(+53.9%) | -$88.72 M(-8.9%) | -$342.53 M(+9.9%) |
| Sep 2022 | - | -$97.39 M(+9.1%) | -$311.78 M(+13.2%) |
| Jun 2022 | - | -$89.25 M(+32.9%) | -$275.47 M(+16.7%) |
| Mar 2022 | - | -$67.18 M(+15.9%) | -$236.13 M(+7.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$222.60 M(+49.7%) | -$57.97 M(-5.1%) | -$219.46 M(+7.9%) |
| Sep 2021 | - | -$61.08 M(+22.4%) | -$203.33 M(+15.2%) |
| Jun 2021 | - | -$49.91 M(-1.2%) | -$176.56 M(+9.2%) |
| Mar 2021 | - | -$50.51 M(+20.7%) | -$161.62 M(+8.7%) |
| Dec 2020 | -$148.72 M(+78.6%) | -$41.84 M(+21.9%) | -$148.72 M(+39.1%) |
| Sep 2020 | - | -$34.31 M(-1.9%) | -$106.88 M(+47.3%) |
| Jun 2020 | - | -$34.97 M(-7.0%) | -$72.57 M(+93.0%) |
| Mar 2020 | - | -$37.61 M | -$37.61 M |
| Dec 2019 | -$83.29 M | - | - |
FAQ
- What is Cerevel Therapeutics Holdings annual EBITDA?
- What is the all time high annual EBITDA for Cerevel Therapeutics Holdings?
- What is Cerevel Therapeutics Holdings annual EBITDA year-on-year change?
- What is Cerevel Therapeutics Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for Cerevel Therapeutics Holdings?
- What is Cerevel Therapeutics Holdings quarterly EBITDA year-on-year change?
- What is Cerevel Therapeutics Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for Cerevel Therapeutics Holdings?
- What is Cerevel Therapeutics Holdings TTM EBITDA year-on-year change?
What is Cerevel Therapeutics Holdings annual EBITDA?
The current annual EBITDA of CERE is -$416.14 M
What is the all time high annual EBITDA for Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings all-time high annual EBITDA is -$83.29 M
What is Cerevel Therapeutics Holdings annual EBITDA year-on-year change?
Over the past year, CERE annual EBITDA has changed by -$73.61 M (-21.49%)
What is Cerevel Therapeutics Holdings quarterly EBITDA?
The current quarterly EBITDA of CERE is -$127.58 M
What is the all time high quarterly EBITDA for Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings all-time high quarterly EBITDA is -$34.31 M
What is Cerevel Therapeutics Holdings quarterly EBITDA year-on-year change?
Over the past year, CERE quarterly EBITDA has changed by -$35.44 M (-38.46%)
What is Cerevel Therapeutics Holdings TTM EBITDA?
The current TTM EBITDA of CERE is -$443.48 M
What is the all time high TTM EBITDA for Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings all-time high TTM EBITDA is -$37.61 M
What is Cerevel Therapeutics Holdings TTM EBITDA year-on-year change?
Over the past year, CERE TTM EBITDA has changed by -$66.94 M (-17.78%)